The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
This performance was primarily driven by the full-label expansion of Elevidys for DMD patients. The company's strong execution in commercializing Elevidys has solidified its position as a leader in ...
The announcement was made at Arab Health 2025 where Sidra Medicine will highlight its international patient service programmes ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback